HR Execs on the Move

Rosmik Design

www.gowms.com

 
Rosmik Design is a Lemon Grove, CA-based company in the Software and Internet sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.gowms.com
  • 3494 Citrus St
    Lemon Grove, CA USA 91945
  • Phone: 619.303.4621

Executives

Name Title Contact Details

Similar Companies

The Crypsis Group

Crypsis helps and protects its clients by defending against and responding to cybersecurity threats.

VOIP-INC

VOIP-INC is a Canoga Park, CA-based company in the Software and Internet sector.

Enterprise Knowledge

Enterprise Knowledge (EK) is a services firm that integrates Knowledge Management, Information Management, Information Technology, and Agile Approaches to deliver comprehensive solutions. Our mission is to form true partnerships with our clients, liste...

Idealliance

Idealliance is a global industry association representing the visual communications industry, comprised of content and media creators, and their print and digital service providers, material suppliers and technology partners. Serving thousands of member companies employing hundreds of thousands of professionals, Idealliance provides an open and cross-industry platform for motivated professionals to create a more sustaining, competitive, and compelling graphic and visual communications industry. The association capitalizes on its integrated capabilities to advance proven technical and management best practices, deliver best-in-class research, education and certification, and lead a connected community toward innovation and inspiration.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.